Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced it will release its financial results for the first quarter ended March 31, 2023, on May 8, 2023, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Vicarious Surgical is focused on advanced surgical robotics with the aim of enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Backed by prominent investors, including Bill Gates and Khosla Ventures, the company is known for its innovative approach that transports surgeons inside patients for minimally invasive surgeries. Stakeholders can access further information via the company's investor website.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in two upcoming investor conferences. The company aims to enhance surgical procedures through innovative robotics technology.
The first event is the Cowen 43rd Annual Healthcare Conference, featuring a fireside chat on March 8th at 9:50 a.m. ET. The second is the Oppenheimer 33rd Annual Healthcare Conference, with a virtual presentation scheduled for March 14th at 1:20 p.m. ET. Live and archived versions of these presentations will be available on the company's website.
Vicarious Surgical reported a cash burn of $67 million for 2022, meeting its objective, and announced initiatives to extend its cash runway. The company expects 2023 cash burn between $55-$65 million. Vicarious Surgical's operating expenses surged to $80.1 million in 2022 versus $38.2 million in 2021, with an adjusted net loss of $78.8 million, or $0.65 per share. Despite a GAAP net income of $5.2 million for the year, the company reported significant losses. Notable achievements include the completion of the Beta 2 robotic system and partnerships with major healthcare providers, enhancing its market position.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
